EVENTS DURING THE THIRD QUARTER
- First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis (July 24)
- Active Biotech expanded US collaboration to advance tasquinimod clinical development in myelofibrosis (August 18)
- Active Biotech announced that global patent protection for laquinimod has been strengthened with Patent Grant in Japan (September 30)
EVENTS AFTER THE END OF THE PERIOD
- First cohort under amended protocol successfully completed safety evaluation in HOVON 172 MF clinical study of tasquinimod in myelofibrosis (October 13)
FINANCIAL SUMMARY
| SEK M | Jul-Sep | Jan-Sep | Full year | ||
| 2026 2025 | 2026 2025 | 2025 | |||
| Net sales | – | – | – | – | – |
| Operating profit/loss | -8,5 | -6.0 | -27.3 | -28.5 | -37.6 |
| Profit/loss after tax | -8,3 | -6.0 | -26.8 | -28.2 | -37.3 |
| Earnings per share (SEK) | -0,32 | -0.49 | -1,02 | -2.29 | -2.77 |
| Cash and cash equivalents (at close of period) | 36.3 | 9.1 | 65.1 | ||
The report is also available at www.activebiotech.com
The information was submitted, through the agency of the contact person below, for public disclosure on 2026-11-05 at 08:30 CEST.